BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pandya DN, Sinha A, Yuan H, Mutkus L, Stumpf K, Marini FC, Wadas TJ. Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography. Molecules 2020;25:E3672. [PMID: 32806623 DOI: 10.3390/molecules25163672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao L, Chen J, Pang Y, Fang J, Fu K, Meng L, Zhang X, Guo Z, Wu H, Sun L, Su G, Lin Q, Chen H. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy. Mol Pharm 2022. [PMID: 35917335 DOI: 10.1021/acs.molpharmaceut.2c00424] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Manafi-farid R, Ataeinia B, Ranjbar S, Jamshidi Araghi Z, Moradi MM, Pirich C, Beheshti M. ImmunoPET: Antibody-Based PET Imaging in Solid Tumors. Front Med 2022;9:916693. [DOI: 10.3389/fmed.2022.916693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wen X, Xu P, Shi M, Liu J, Zeng X, Zhang Y, Shi C, Li J, Guo Z, Zhang X, Khong PL, Chen X. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics 2022;12:422-33. [PMID: 34987657 DOI: 10.7150/thno.68182] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
4 Ruiz-López E, Calatayud-Pérez J, Castells-Yus I, Gimeno-Peribáñez MJ, Mendoza-Calvo N, Morcillo MÁ, Schuhmacher AJ. Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography. Cancers (Basel) 2021;14:74. [PMID: 35008238 DOI: 10.3390/cancers14010074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Lindner T, Giesel FL, Kratochwil C, Serfling SE. Radioligands Targeting Fibroblast Activation Protein (FAP). Cancers (Basel) 2021;13:5744. [PMID: 34830898 DOI: 10.3390/cancers13225744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
6 Shi Y, Kong Z, Liu P, Hou G, Wu J, Ma W, Cheng X, Wang Y. Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors. Cells 2021;10:1142. [PMID: 34068501 DOI: 10.3390/cells10051142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Windisch P, Zwahlen DR, Giesel FL, Scholz E, Lugenbiel P, Debus J, Haberkorn U, Adeberg S. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review. EJNMMI Res 2021;11:18. [PMID: 33606104 DOI: 10.1186/s13550-021-00761-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]